mii-exa-mtb-therapieplan-kombinationstherapie - MII IG Kerndatensatz-Modul Molekulares Tumorboard v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example CarePlan: mii-exa-mtb-therapieplan-kombinationstherapie

English

Profile: MII PR MTB Therapieplan version: 2027.0.0-ballot.1

status: Active

intent: Plan

category: posttherapeutische Tumorkonferenz (manche Tumore werden nicht operiert)

subject: Maxim Muster (no stated gender), DoB Unknown

created: 2024-08-09

Activities

Reference

RequestGroup: extension = 1,https://doi.org#10.1002/gcc.23222,Case study or single unusual responder indicates the biomarker is associated with response to the drug in the same tumor type.; status = active; intent = proposal; authoredOn = 2024-01-01

IG © 2024+ Medizininformatik-Initiative. Package de.medizininformatikinitiative.kerndatensatz.mtb#2027.0.0-ballot.1 based on FHIR 4.0.1. Generated 2026-09-15
Links: Table of Contents | QA Report | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Legal notice
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.